Kailo Pharma
Peptide-based Nasal Spray in Preclinical Development Targeting PTSD
Company Overview
Snapshot
Founded in February 2026 by Dr. Iris Reuveni and Prof. Edi Barkai, Kailo Pharma operates with 1–10 employees. The company has raised $2.1M across one funding round from two investors. In March 2026, Kailo Pharma secured its Pre-Seed funding round, led by.
Business overview
Kailo Pharma is an Israeli medical startup focused on developing a novel treatment for Post-Traumatic Stress Disorder (PTSD). The company's core technology is a peptide-based therapy designed for nasal delivery, targeting a newly identified brain mechanism associated with the pathological amplification of traumatic memories. Kailo Pharma aims to weaken the intensity of trauma without affecting normal memory, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In March 2026, Kailo Pharma announced its Pre-Seed funding round, signaling investor confidence in its innovative approach to PTSD treatment. This development highlights the growing interest in advanced therapeutic solutions for neurological disorders and positions Kailo Pharma as a key player in the development of peptide-based therapies for central nervous system conditions.
Log in to access full profile ›Company Intelligence Q&A
- When was Kailo Pharma founded?
- Kailo Pharma was founded in February 2026.
- Who are the founders of Kailo Pharma?
- Kailo Pharma was founded by Dr. Iris Reuveni and Prof. Edi Barkai.
- What is Kailo Pharma's primary focus?
- Kailo Pharma is focused on commercializing University of Haifa research to directly treat PTSD using a peptide-based nasal spray.
- What was Kailo Pharma's most recent funding event?
- In March 2026, Kailo Pharma secured its Pre-Seed funding round, led by.
- What is the total capital raised by Kailo Pharma?
- Kailo Pharma has raised a total of $2.1M across one funding round.